

§Appl. No. 10/076,421
Amdt. dated September 13, 2004
Reply to Office Action of, April 13, 2004

Listing of Claims:

Please **amend** the claims as follows:

Claim 1 (Cancelled)

Claim 2 (Cancelled)

Claim 3 (Cancelled)

Claim 4 (Cancelled)

Claim 5 (Cancelled)

Claim 6 (Withdrawn) The anti-HIV agent of claim 1, wherein the ligand molecule binding to CD87 is an anti-CD87 antibody.

Claim 7 (Withdrawn) The anti-HIV agent of claim 1, wherein the ligand molecule binding to CD87 is a fragment of or an analogue to an anti-CD87 antibody, wherein the fragment or analogue has a specific binding affinity to CD87.

Claim 8 (Cancelled)

Claim 9 (Withdrawn) A method for screening for an anti-HIV agent comprising separately bringing compounds to be tested into contact with CD87 and selecting from the compounds a compound that specifically binds to CD87.

Claim 10 (Withdrawn) A method for preparing an anti-HIV pharmaceutical preparation comprising the steps of separately bringing compounds to be tested into contact with CD87 and selecting from the compounds a compound that specifically binds to CD87, confirming that the

§Appl. No. 10/076,421
Amdt. dated September 13, 2004
Reply to Office Action of, April 13, 2004

selected compound has an anti-HIV activity, and providing the compound confirmed to have an anti-HIV activity, as an anti-HIV agent, in the form of a pharmaceutical preparation to be administered to a human.

Claim 11 (Withdrawn) A method for screening for an anti-HIV agent comprising the steps of providing a co-culture system comprising cells chronically infected with HIV and non-infected cells, separately performing co-culture after addition of a known concentration of compounds to be tested to the co-culture system, measuring the amount of the HIV particles released into the supernatant of the co-culture, comparing the measured amount of the HIV particles with the amount of the HIV particles released into the supernatant of the co-culture that is performed without addition of any of the compounds to be tested, and selecting as an anti-HIV agent a tested compound that exhibits inhibition of release of HIV particles based on the result of the comparison.

Claim 12 (Withdrawn) A method for preparing an anti-HIV pharmaceutical preparation comprising the steps of providing a co-culture system comprising cells chronically infected with HIV and non-infected cells, separately performing co-culture after addition of a known concentration of compounds to be tested to the co-culture system, measuring the amount of the HIV particles released into the supernatant of the co-culture, comparing the measured amount of the HIV particles with the amount of the HIV particles released into the supernatant of the co-culture that is performed without addition of any of the compounds to be tested, selecting as an anti-HIV agent a tested compound that exhibits inhibition of release of HIV particles based on the result of the comparison, and providing the anti-HIV agent in the form of a pharmaceutical preparation to be administered to a human.

§Appl. No. 10/076,421
Amdt. dated September 13, 2004
Reply to Office Action of, April 13, 2004

Claim 13 (Withdrawn) A method for treating an HIV-infected human for suppression of reproduction of HIV in the human comprising administering to the human an HIV reproduction-suppressive amount of a ligand molecule binding to CD87.

Claim 14 (Withdrawn) The method of claim 13 wherein the ligand molecule binding to CD87 is the high molecular weight urokinase-type plasminogen activator.

Claim 15 (Withdrawn) The method of claim 14 wherein the ligand molecule binding to CD87 is a fragment of or a analogue to the high molecular weight urokinase-type plasminogen activator, wherein the fragment or the analogue has a specific binding affinity to CD87.

Claim 16 (Withdrawn) The method of claim 14 wherein the ligand molecule binding to CD87 is ATF.

Claim 17 (Withdrawn) The method of claim 14 wherein the ligand molecule binding to CD87 is a fragment of or an analogue to ATF, wherein the fragment or the analogue has a specific binding affinity to CD87.

Claim 18 (Withdrawn) The method of claim 14 wherein the ligand molecule binding to CD87 is an anti-CD87 antibody.

Claim 19 (Withdrawn) The method of claim 14 wherein the ligand molecule binding to CD87 is a fragment of or an analogue to an anti-CD87 antibody, wherein the fragment or analogue has a specific binding affinity to CD87.

§Appl. No. 10/076,421
Amdt. dated September 13, 2004
Reply to Office Action of, April 13, 2004

Claim 20 (Withdrawn) Use of a ligand molecule binding to CD87 for the manufacture of a pharmaceutical composition for suppression of reproduction of HIV in a human infected with HIV.

Claim 21 (Withdrawn) The use of claim 20 wherein the ligand molecule binding to CD87 is the high molecular weight urokinase-type plasminogen activator.

Claim 22 (Withdrawn) The use of claim 20 wherein the ligand molecule binding to CD87 is a fragment of or a analogue to the high molecular weight urokinase-type plasminogen activator, wherein the fragment or the analogue has a specific binding affinity to CD87.

Claim 23 (Withdrawn) The use of claim 20 wherein the ligand molecule binding to CD87 is ATF.

Claim 24 (Withdrawn) The use of claim 20 wherein the ligand molecule binding to CD87 is a fragment of or an analogue to ATF, wherein the fragment or the analogue has a specific binding affinity to CD87.

Claim 25 (Withdrawn) The use of claim 20 wherein the ligand molecule binding to CD87 is an anti-CD87 antibody.

Claim 26 (Withdrawn) The use of claim 20 wherein the ligand molecule binding to CD87 is a fragment of or an analogue to an anti-CD87 antibody, wherein the fragment or analogue has a specific binding affinity to CD87.

§Appl. No. 10/076,421
Amdt. dated September 13, 2004
Reply to Office Action of, April 13, 2004

Claim 27 (New) An anti-HIV-1 pharmaceutical composition for injection comprising:
an amino-terminal fragment of the high molecular weight urokinase-type plasminogen activator (HMW-uPA) as an active component, the fragment being contained in a sterile aqueous or non-aqueous medium, wherein the fragment comprises amino acids 21-155 of the prepro-urokinase (sc-uPA) and does not extend beyond amino acid 178 of the sc-uPA.

Claim 28 (New) The anti-HIV-1 pharmaceutical composition of claim 27, wherein the fragment consists of amino acids 21-155 of the sc-uPA.

Claim 29 (New) An anti-HIV-1 pharmaceutical composition for injection comprising:
an amino-terminal fragment of the high molecular weight urokinase-type plasminogen activator (HMW-uPA) as an active component, the fragment being contained in a sterile aqueous or non-aqueous medium, wherein the fragment contains an EGF-like domain, a Kringle domain and a urokinase receptor binding domain of the high molecular weight urokinase-type plasminogen activator (HMW-uPA) and no portion of the B chain of the HMW-uPA.

Claim 30 (New) The anti-HIV-1 pharmaceutical composition of one of claims 27-29,
wherein the aqueous medium is selected from the group consisting of water and an aqueous solution of one or more pharmaceutically acceptable inert solutes and the non-aqueous medium is selected from the group consisting of polyalcohols, vegetable oils and organic esters.

Claim 31 (New) An anti-HIV-1 pharmaceutical composition for transnasal or transpulmonary application in the form of a dry powder consisting of an amino-terminal fragment of the high molecular weight urokinase-type plasminogen activator (HMW-uPA) as an active component and a carrier, wherein the fragment comprises amino acids 21-155 of the prepro-urokinase (sc-uPA) and does not extend beyond amino acid 178 of the sc-uPA.

§Appl. No. 10/076,421
Amdt. dated September 13, 2004
Reply to Office Action of, April 13, 2004

Claim 32 (New) The anti-HIV-1 pharmaceutical composition of claim 31 wherein the fragment consists of amino acids 21-155 of the sc-uPA.

Claim 33 (New) An anti-HIV-1 pharmaceutical composition for transnasal or pulmonary application in the form of a dry powder consisting of an amino-terminal fragment of the high molecular weight urokinase-type plasminogen activator (HMW-uPA) as an active component and a carrier, wherein the fragment contains an EGF-like domain, a Kringle domain and a urokinase receptor binding domain of the high molecular weight urokinase-type plasminogen activator (HMW-uPA) and no portion of the B chain of the HMW-uPA.

Claim 34 (New) The anti-HIV-1 pharmaceutical composition of one of claims 31 to 33, wherein the carrier is at least one compound selected from the group consisting of monosaccharides, disaccharides, polysaccharides, sugar alcohols, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, nonionic surfactants, gelatin, casein, polyethylene glycol and hydrogenated lecithin.